119 related articles for article (PubMed ID: 1310102)
1. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
2. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
[TBL] [Abstract][Full Text] [Related]
4. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
[TBL] [Abstract][Full Text] [Related]
5. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
6. Intravenous delivery of 5'-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: results of a pilot study.
Epstein AH; Lebovics RS; Van Waes C; Smith J; Okunieff P; Cook JA
Laryngoscope; 1998 Jul; 108(7):1090-4. PubMed ID: 9665262
[TBL] [Abstract][Full Text] [Related]
7. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
8. Theoretical basis and clinical methodology for stereotactic interstitial brain tumor irradiation using iododeoxyuridine as a radiation sensitizer and 145Sm as a brachytherapy source.
Goodman JH; Gahbauer RA; Kanellitsas C; Clendenon NR; Laster BH; Fairchild RG
Stereotact Funct Neurosurg; 1990; 54-55():531-4. PubMed ID: 1964244
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts.
Buchegger F; Adamer F; Schaffland AO; Kosinski M; Grannavel C; Dupertuis YM; de Tribolet N; Mach JP; Delaloye AB
Int J Cancer; 2004 May; 110(1):145-9. PubMed ID: 15054880
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
11. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
12. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
[TBL] [Abstract][Full Text] [Related]
13. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
14. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy.
Mizumoto M; Yamamoto T; Takano S; Ishikawa E; Matsumura A; Ishikawa H; Okumura T; Sakurai H; Miyatake S; Tsuboi K
Pract Radiat Oncol; 2015; 5(1):e9-16. PubMed ID: 25413424
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
17. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.
Robertson JM; Sondak VK; Weiss SA; Sussman JJ; Chang AE; Lawrence TS
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):87-92. PubMed ID: 7995772
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.
Kinsella TJ; Dobson PP; Mitchell JB; Fornace AJ
Int J Radiat Oncol Biol Phys; 1987 May; 13(5):733-9. PubMed ID: 3570896
[TBL] [Abstract][Full Text] [Related]
19. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
20. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
